Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06008860 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

Study acronym: COVID-19
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2025 to Dec 2026v7
  2. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Jul 2025 to Dec 2025
    • Eligibility criteria shortened, about 16 words
    v6
  3. Eligibility criteria expanded, about 1 wordv5
  4. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Jul 2024 to Jul 2025
    v4
  5. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v3
  6. Primary endpoint revised
    • Secondary endpoints revised (3)
    • Study description expanded, about 3 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
Trial Details
NCT Number NCT06008860
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov